Sensus Healthcare, Inc. (SRTS) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals declining financial metrics, including reduced units sold, gross profit, and increased net loss, indicating weakening financial health. Despite some positive elements, like international expansion and potential breakeven in Q4, the negative trends, including a significant drop in gross margin and increased operating expenses, dominate. The Q&A section did not alleviate concerns, as management's responses lacked clarity on critical timelines. Given these factors, the stock is likely to experience a negative reaction in the near term.
Key Financial Performance
Revenues for Q3 2025 $6.9 million, compared with $8.8 million for Q3 2024, a decrease primarily driven by a lower number of units sold to a larger customer, slightly offset by revenue recognized from the new placement program under the Fair Deal Agreement in 2025.
Number of units sold in Q3 2025 16 units, compared to 27 units in Q3 2024, reflecting a decrease in sales.
Gross profit for Q3 2025 $2.7 million, compared with $5.2 million in Q3 2024, a decrease due to lower sales, higher costs of servicing systems, and costs associated with the Fair Deal Agreement program.
Gross margin for Q3 2025 39.1%, compared to 59.1% in Q3 2024, reflecting lower sales and higher costs.
Total operating expenses for Q3 2025 $5.3 million, compared with $3.7 million in Q3 2024, an increase due to higher IT and professional service fees, compensation, headcount, payroll costs, and lobbying costs related to billing code reimbursement.
Net loss for Q3 2025 $0.9 million, or $0.06 per share, compared with net income of $1.2 million, or $0.07 per diluted share, in Q3 2024, reflecting lower revenues and higher operating expenses.
Adjusted EBITDA for Q3 2025 Negative $2.4 million, compared with $1.6 million in Q3 2024, reflecting lower revenues and higher costs.
Revenues for the first 9 months of 2025 $22.5 million, compared with $28.7 million for the first 9 months of 2024, a decrease due to fewer units sold to a large customer, slightly offset by revenue from the Fair Deal Agreement program.
Number of units sold in the first 9 months of 2025 56 units, compared to 76 units in the first 9 months of 2024, reflecting a decrease in sales.
Gross profit for the first 9 months of 2025 $10 million, or 44.4% of revenues, compared with $17.3 million, or 60.3% of revenues, for the first 9 months of 2024, reflecting lower sales and higher costs.
Net loss for the first 9 months of 2025 $4.6 million, or $0.28 per share, compared with net income of $5.1 million, or $0.31 per diluted share, for the first 9 months of 2024, reflecting lower revenues and higher operating expenses.
Adjusted EBITDA for the first 9 months of 2025 Negative $6.7 million, compared with $6.7 million in the first 9 months of 2024, reflecting lower revenues and higher costs.
Cash position at the end of Q3 2025 $24.5 million, up from approximately $22 million at the end of 2024, driven by improved working capital management and ongoing collections.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New CPT Codes for SRT: CMS published first-ever dedicated CPT codes for superficial radiotherapy (SRT) in nonmelanoma skin cancer and keloids, increasing reimbursement per fraction by over 300%.
Sentinel Software Platform: Ongoing development of Sentinel platform to enhance data storage, diagnostics, and analytics. Sentinel 2.0 initiative underway with expected results in 2026.
Transdermal Infusion (TDI) System: Awaiting FDA feedback; refining training pathways and support models for future rollout.
International Expansion: Shipped 3 SRT systems to China; MDSAP certification enables access to markets like Canada, Brazil, Japan, and Australia. Initial sales under certification expected soon.
Trade Show in Japan: Sensus will exhibit at JASTRO, Japan's largest radiation oncology conference, marking its first trade show in Japan.
Fair Deal Agreement Program: FDA treatment volumes increased 20% from Q2 and 52% from Q1. Quarterly treatment volumes have risen 157% since program launch.
Inventory and Cash Position: Ended Q3 with $24.5 million in cash and close to 100 SRT systems in inventory, ensuring readiness for anticipated demand.
Focus on Dermatology Practices: New CPT codes narrow reimbursement gap between office-based and hospital outpatient rates, potentially expanding SRT adoption in dermatology offices.
R&D Investment: Increased R&D spending on lobbying for billing code reimbursement and next-generation system development.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Decline: Revenues for the third quarter of 2025 decreased to $6.9 million from $8.8 million in the same quarter of 2024, primarily due to a lower number of units sold to a large customer.
Gross Margin Decline: Gross margin dropped to 39.1% in Q3 2025 from 59.1% in Q3 2024, driven by lower sales, higher servicing costs, and costs associated with the Fair Deal Agreement program.
Increased Operating Expenses: Total operating expenses rose to $5.3 million in Q3 2025 from $3.7 million in Q3 2024, with increases in general and administrative, selling and marketing, and research and development expenses.
Net Loss: The company reported a net loss of $0.9 million in Q3 2025 compared to a net income of $1.2 million in Q3 2024, reflecting financial challenges.
Inventory Risks: The company holds approximately $13 million in finished goods inventory, which could pose risks if anticipated demand does not materialize.
International Expansion Challenges: While international expansion is underway, the process is expected to take up to 12 months in certain regions, potentially delaying revenue contributions.
Regulatory Uncertainty: Awaiting feedback from the FDA on the Transdermal Infusion (TDI) system, which could delay its commercial rollout and impact future revenue streams.
Competitive Pressures: The company faces competitive pressures as it works to expand adoption of its SRT technology in dermatology offices and international markets.
Economic Pressures: Higher costs of servicing systems and increased lobbying and product development expenses are straining financial resources.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Future demand expectations: CMS published first-ever dedicated CPT codes for superficial radiotherapy in nonmelanoma skin cancer and keloids, increasing reimbursement per fraction by over 300%. This is expected to drive strong interest and rising demand for SRT systems.
SRT system sales projection: The company expects to reach 1,000 systems sold globally by 2026, up from over 900 systems currently sold.
Fair Deal Agreement program growth: FDA treatment volumes increased 20% from the second quarter, marking the third consecutive quarter of double-digit growth. This growth is expected to continue through the end of the year.
Sentinel software platform development: The company has initiated an expanded R&D program for the next generation of the Sentinel platform, called Sentinel 2.0, with initial results expected in 2026. This platform aims to enhance analytics, reporting capabilities, and customer-facing tools.
International expansion: The company is building a foundation for global expansion, with initial sales under MDSAP certification expected soon. International sales are anticipated to ramp gradually over the next 12 months, with meaningful contributions over time.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What has been the impact of LCD reimbursement changes for ultrasound-guided SRT systems this quarter, and what is the update on its future impact?
A:The reduction in ultrasound utilization by CMS has had minimal impact due to the FDA model not using ultrasound for every fraction. The 300% increase in fractionation reimbursement code offsets the reduction, making the impact negligible or even beneficial for physicians.
Q:Can you provide utilization trend metrics for this quarter?
A:Utilization increased by 20% from Q2 to Q3 and by 152% year-to-date. The trend is expected to continue as patients prefer noninvasive SRT technology.
Q:What factors might accelerate placements in the U.S. in Q4?
A:There is pent-up demand due to a halt in orders following the LCD release. With clarity on reimbursement codes starting January 1, customers are expected to line up for purchases, potentially leading to breakeven or profitability in Q4.
Q:Will there be a shift between SRT-100 and Vision systems due to reimbursement changes?
A:There may be an uptick in SRT-100 sales, but the Vision system remains important due to its Sentinel operating system. A Sentinel 2.0 version is being developed to give SRT-100 similar capabilities, ensuring both products meet market demands.
Q:What is the status of the LCD and its impact on ultrasound imaging?
A:The LCD is considered nonoperative and baseless, as CMS has introduced a code for ultrasound in SRT, recognizing its clinical importance. Efforts will continue to improve reimbursement for ultrasound imaging.
Q:What is the timeline for the 11 pending sites to go live?
A:The company believes the 11 pending sites will go live in Q4 and expects to add more sites.
Q:How will CPT code reimbursement changes impact deal flow and utilization?
A:The changes are expected to increase sales of the lower-cost SRT-100 and stabilize reimbursement, making it undeniable. This will benefit both FDA and direct purchase models, improving ROI for doctors.
Q:What is the anticipated ramp for international sales and its impact on margins?
A:International sales are expected to grow to 20% of total revenue within 12-24 months, up from the current 5-10%. The Vision system is gaining traction internationally, with plans to submit for regulatory clearance in China.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing the exact timeline for the 11 pending sites to go live, only stating their belief that they will go live in Q4. Additionally, while they acknowledged the lower valuation of the ultrasound code, they did not provide specific plans or timelines for improving it.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Agreement program
CMS
CPT code
China interest
Deal Agreement
Fair Deal
SRT code
Sentinel platform
adoption
certainty
code reimbursement
customer placement
demand SRT
development generation
efficiency
engagement
expansion
expense month
face
generation system
headcount increase
income month
increase product
lobbying
location
month period
number unit
payroll commission
period increase
physician
placement program
program Fair
servicing system
share period
system Fair
trend
turnkey model
utilization
week
SRTS Transcript
Sensus Healthcare, Inc. (SRTS) Q1 2026 Earnings Call Transcript
Unknown5-8
The earnings call reveals mixed signals. While the company faces financial strain with a negative EBITDA and net loss, it shows potential for growth with expanding international sales and recurring revenue streams. The absence of sales to the largest customer is a setback, but there's optimism for future returns. The Q&A highlights interest in new CPT codes, indicating potential for future revenue growth. However, the lack of clear timelines for revenue inflection and the ongoing financial strain balance out the positives, resulting in a neutral sentiment for the stock price movement.
Sensus Healthcare, Inc. (SRTS) Q4 2025 Earnings Call Transcript
Unknown2-12
The company reported disappointing financial results with significant revenue and profit declines, resulting in a net loss. Despite optimistic guidance and international expansion plans, uncertainties like the largest customer's exclusion from projections, unclear FDA approval timelines, and vague management responses during the Q&A raise concerns. Increased expenses and negative EBITDA further contribute to a negative sentiment. Although there is potential in international markets and reimbursement changes, the overall outlook remains negative due to financial underperformance and uncertainties.
Sensus Healthcare, Inc. (SRTS) Q3 2025 Earnings Call Transcript
Unknown11-6
The earnings call reveals declining financial metrics, including reduced units sold, gross profit, and increased net loss, indicating weakening financial health. Despite some positive elements, like international expansion and potential breakeven in Q4, the negative trends, including a significant drop in gross margin and increased operating expenses, dominate. The Q&A section did not alleviate concerns, as management's responses lacked clarity on critical timelines. Given these factors, the stock is likely to experience a negative reaction in the near term.
Sensus Healthcare, Inc. (SRTS) Q2 2025 Earnings Call Transcript
Unknown8-8
The earnings call revealed significant declines in gross profit, gross margin, and a shift from net income to net loss, indicating financial challenges. The Q&A highlighted uncertainties around CMS reimbursement, impacting sales and causing a large customer to pause purchases. Despite some international sales optimism, the lack of clear guidance on reimbursement and increased operating expenses suggest a negative short-term outlook. The overall sentiment leans negative due to financial performance issues and unresolved reimbursement concerns.
SRTS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
